From a medical cardiologist’s perspective, which patient subgroups in your practice do you feel represent ideal candidates for deployment of PCSK9 inhibitors to lower LDL-C levels, based on the results of the ODYSSEY Outcomes and FOURIER Trials?

Name: From a medical cardiologist’s perspective, which patient subgroups in your practice do you feel represent ideal candidates for deployment of PCSK9 inhibitors to lower LDL-C levels, based on the results of the ODYSSEY Outcomes and FOURIER Trials?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Robert Rosenson, MD

Professor of Medicine (Cardiology)
Mount Sinai Icahn School of Medicine
Director, Cardiometabolics Unit
Mount Sinai Heart Institute
New York, NY